Soterix Medical

Soterix Medical announces phase III trial for depression

Tuesday, November 5, 2013

Soterix Medical has announced a phase III trial for Major Depressive Disorder (MDD), which will compare Soterix Medical’s Transcranial Direct Current Stimulation (tDCS) Limited Total Energy (LTE) technology against a fully dosed, effective antidepressant Escitalopram oxalate (Lexapro). The seminal ELECT-TDCS study, initiated by Dr. Andre Brunoni of the University of Sao Paulo, builds on prior work. This work combined tDCS with antidepressant sertraline and concluded “in MDD, the combination of tDCS and sertraline increases the efficacy of each treatment. The efficacy and safety of tDCS and sertraline did not differ.”

[Read More]